Alpha Tau Medical (DRTS) Net Cash Flow (2021 - 2022)

Alpha Tau Medical (DRTS) posted quarterly Net Cash Flow of -$86.3 million for Q2 2022, down 214.92% on a QoQ basis from $75.1 million in Q1 2022.

Alpha Tau Medical (DRTS) Net Cash Flow (2021 - 2022) Analysis & Trends

Alpha Tau Medical (DRTS) has reported Net Cash Flow for 2 consecutive years, with -$86.3 million the latest figure, recorded in Q2 2022.

Quarterly Net Cash Flow changed N/A year-over-year to -$86.3 million in Q2 2022, while the trailing twelve-month figure through Mar 2023 was -$86.3 million (down 214.92% YoY) and the FY2025 annual result came in at -$1.5 million, down 248.61% from the prior year.
Net Cash Flow eased to -$86.3 million in Q2 2022 per DRTS's latest filing, from $75.1 million in the prior quarter.
Over the last five years, Net Cash Flow for DRTS reached as high as $75.1 million in Q1 2022 and fell as low as -$86.3 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Cash Flow (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	10.56 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	224.46 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-1.34 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	457.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-152.20 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	57.19 Mn
10	Alpha Tau Medical	1.19 Bn	1.11 Bn	-	-

Download Data